Cost-Effectiveness Analysis of Interventional Liver-Directed Therapies for a Single, Small Hepatocellular Carcinoma in Liver Transplant Candidates

被引:3
作者
Wu, Xiao [1 ]
Heller, Michael [1 ]
Kwong, Allison [3 ]
Fidelman, Nicholas [1 ]
Mehta, Neil [2 ]
机构
[1] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Dept Gen Hepatol & Liver Transplantat, 513 Parnassus Ave,Room S-357, San Francisco, CA 94143 USA
[3] Stanford Univ, Dept Gastroenterol & Hepatol, San Francisco, CA USA
关键词
TRANSARTERIAL CHEMOEMBOLIZATION; RADIOFREQUENCY ABLATION; TRENDS; RESECTION; OUTCOMES; SCORE; Y-90;
D O I
10.1016/j.jvir.2023.02.016
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose: To assess the cost effectiveness of 3 main locoregional therapies (LRTs) (transarterial chemoembolization [TACE], transarterial radioembolization [TARE], and percutaneous ablation) as bridging therapy.Materials and Methods: A cost-effectiveness analysis was performed comparing the 3 LRTs for patients with a single hepatocellular carcinoma (HCC) with a diameter of 3 cm or less over a 5-year time horizon from a payer's perspective. The clinical courses, including transplantation, decompensation resulting in delisting, and the need for a second LRT, were based on data from the United Network for Organ Sharing (2016-2019). Costs and effectiveness were measured in U.S. dollars and quality-adjusted life-years, respectively. Probabilistic and deterministic sensitivity analyses were performed. Results: A total of 2,594, 1,576, and 903 patients underwent TACE, ablation, and TARE, respectively. Ablation was the dominant strategy, with the lowest expected cost and highest effectiveness. The probabilistic sensitivity analysis demon-strated that ablation was the most cost-effective strategy in 93.9% of simulations. A subgroup analysis was performed for different wait times, with ablation remaining the most cost-effective strategy. The sensitivity analysis showed that ablation was most effective if the risk of waitlist dropout was less than 2.00% and the rate of transplantation was more than 15.1% quarterly. TARE was most effective if the risk of dropout was less than 1.19% and the rate of transplantation was more than 24.0%. TACE was most effective if the risk of dropout was less than 1.01% and the rate of transplantation was more than 45.7%. Ablation remained the most cost-effective modality until its procedural cost was more than $34,843.Conclusions: Ablation is the most cost-effective bridging strategy for patients with a single, small (& LE;3 cm) HCC prior to liver transplantation. The conclusion remained robust in multiple sensitivity analyses.
引用
收藏
页码:1237 / 1246.e3
页数:13
相关论文
共 50 条
  • [31] Liver-directed combined radiotherapy as a bridge to curative surgery in locally advanced hepatocellular carcinoma beyond the Milan criteria
    Lee, Won Hee
    Byun, Hwa Kyung
    Choi, Jin Sub
    Choi, Gi Hong
    Han, Dai Hoon
    Joo, Dong Jin
    Kim, Do Young
    Han, Kwang-Hyub
    Seong, Jinsil
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : 1 - 7
  • [32] Cost-Effectiveness Analysis of Stereotactic Ablative Body Radiation Therapy Compared With Surgery and Radiofrequency Ablation in Two Patient Cohorts: Metastatic Liver Cancer and Hepatocellular Carcinoma
    Jin, H.
    Chalkidou, A.
    Hawkins, M.
    Summers, J.
    Eddy, S.
    Peacock, J. L.
    Coker, B.
    Kartha, M. R.
    Good, J.
    Pennington, M.
    CLINICAL ONCOLOGY, 2021, 33 (03) : E143 - E154
  • [33] Improving Adjuvant Liver-Directed Treatment Recommendations for Unresectable Hepatocellular Carcinoma: An Artificial Intelligence-Based Decision-Making Tool
    Mo, Allen
    Velten, Christian
    Jiang, Julie M.
    Tang, Justin
    Ohri, Nitin
    Kalnicki, Shalom
    Mirhaji, Parsa
    Nemoto, Kei
    Aasman, Boudewijn
    Garg, Madhur
    Guha, Chandan
    Brodin, N. Patrik
    Kabarriti, Rafi
    JCO CLINICAL CANCER INFORMATICS, 2022, 6
  • [34] Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis
    Chen, Shuling
    Peng, Zhenwei
    Wei, Mengchao
    Liu, Weifeng
    Dai, Zihao
    Wang, Haibo
    Mei, Jie
    Cheong, Mingfong
    Zhang, Hanmei
    Kuang, Ming
    BMC CANCER, 2018, 18
  • [35] Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis
    Kulik, Laura
    Heimbach, Julie K.
    Zaiem, Feras
    Almasri, Jehad
    Prokop, Larry J.
    Wang, Zhen
    Murad, M. Hassan
    Mohammed, Khaled
    HEPATOLOGY, 2018, 67 (01) : 381 - 400
  • [36] Microwave Ablation as Bridging to Liver Transplant for Patients with Hepatocellular Carcinoma: A Single-Center Retrospective Analysis
    Couillard, Allison B.
    Knott, Emily A.
    Zlevor, Annie M.
    Mezrich, Joshua D.
    Cristescu, Mircea M.
    Agarwal, Parul
    Ziemlewicz, Timothy J.
    Longhurst, Colin
    Lubner, Meghan G.
    Hinshaw, J. Louis
    Said, Adnan
    Laeseke, Paul F.
    Lucey, Michael R.
    Rice, John P.
    Foley, David
    Al-Adra, David
    Lee, Fred T., Jr.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2022, 33 (09) : 1045 - 1053
  • [37] Appraisal of Long-Term Outcomes of Liver-Directed Concurrent Chemoradiotherapy for Hepatocellular Carcinoma with Major Portal Vein Invasion
    Han, Sojung
    Lee, Hye Won
    Park, Jun Yong
    Kim, Seung Up
    Kim, Young
    Ahn, Sang Hoon
    Han, Kwang-Hyub
    Seong, Jinsil
    Won, Jong Yun
    Han, Dai Hoon
    Kim, Beom Kyung
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2020, 7 : 403 - 412
  • [38] Validation of a dropout assessment model of candidates with/without hepatocellular carcinoma on a common liver transplant waiting list
    Toso, Christian
    Majno, Pietro
    Berney, Thierry
    Morel, Philippe
    Mentha, Gilles
    Combescure, Christophe
    TRANSPLANT INTERNATIONAL, 2014, 27 (07) : 686 - 695
  • [39] Cost-benefit analysis of hepatic resection, radiofrequency ablation and liver transplantation in small hepatocellular carcinoma
    Jiao, Xue-Li
    Li, Shou-Chuan
    Hao, Lei
    Wang, Ting-Gang
    Chen, Jian-Feng
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (02) : 307 - 313
  • [40] Single centre experience of liver resection for hepatocellular carcinoma in patients outside transplant criteria
    Chu, F.
    Morris, D. L.
    EJSO, 2006, 32 (05): : 568 - 572